Beta · prototype— This site is under construction: rankings, texts and features change every week.

eMed

Active#4 worldwide · Telemedicine

Telemedicine

HQUnited States
Last roundSeries A · Mar 2026

Uback rankings

How the AI ranks →
RankingTierRankEditionNext update
Telemedicine · worldwideTop 10#4Edition 0 (beta) · Sep 20262 Jan 2027
Rank historySep 2026 · #4 TelemedicineFirst edition: no movements yet.

Estimated valuation

AI · Telemedicine ranking (worldwide)
≈ USD 2.1bnUSD 1.7–2.6bn · Unicorn High confidence
Anchor
Last known equity round: Series A · USD 200M · Mar 2026
Published valuation
over USD 2B · Mar 2026

An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method

Funding history

DateRoundAmountTypeInvestorsSource
Mar 2026Series AUSD 200MEquityAon Consulting, Tom Brady, Joe Lonsdale, Antonio Graciasfiercehealthcare.com

Rounds as cited by Uback’s rankings and their sources. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of eMed as a PDF, on one of three angles only:

ValuationWhat is eMed worth?
Versus competitorsHow does it compare?
Who should acquire itStrategic buyers, and why
Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication and never change the rank.

Comparable companies in telemedicine

Full telemedicine ranking →

Investors in eMed: Aon Consulting · Tom Brady · Joe Lonsdale · Antonio Gracias

Sources. fiercehealthcare.com · mobihealthnews.com

Last updated: Sep 2026Report an error

Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.